Disease Information
General Information of the Disease (ID: DIS00095)
Name |
Testicular cancer
|
---|---|
ICD |
ICD-11: 2C80
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
EADR: Epigenetic Alteration of DNA, RNA or Protein
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Cisplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-106b-5p | [1] | |||
Resistant Disease | Seminoma [ICD-11: 2C80.3] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Regulation | hsa04151 | ||
In Vitro Model | TCam-2 cells | Testicle | Homo sapiens (Human) | CVCL_T012 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. | |||
Key Molecule: hsa-miR-106b-5p | [1] | |||
Resistant Disease | Seminoma [ICD-11: 2C80.3] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Regulation | hsa04151 | ||
In Vitro Model | TCam-2 cells | Testicle | Homo sapiens (Human) | CVCL_T012 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. | |||
Key Molecule: H19, imprinted maternally expressed transcript (H19) | [1] | |||
Resistant Disease | Seminoma [ICD-11: 2C80.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Regulation | hsa04151 | ||
In Vitro Model | TCam-2 cells | Testicle | Homo sapiens (Human) | CVCL_T012 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Testis development-related protein 1 (TDRG1) | [1] | |||
Resistant Disease | Seminoma [ICD-11: 2C80.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Regulation | hsa04151 | ||
In Vitro Model | TCam-2 cells | Testicle | Homo sapiens (Human) | CVCL_T012 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis; RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. | |||
Key Molecule: G1/S-specific cyclin-D1 (CCND1) | [2] | |||
Resistant Disease | Testicular germ cell tumor [ICD-11: 2C80.2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | Susa cells | Thyroid gland | Homo sapiens (Human) | CVCL_L280 |
GCT27 cells | Thyroid gland | Homo sapiens (Human) | CVCL_A344 | |
833K cells | Abdomen | Homo sapiens (Human) | CVCL_2292 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
ATP cell viability assay | |||
Mechanism Description | CCND1 may induce cisplatin resistance both through cell cycle control and inhibition of cellular apoptosis pathways, which have been previously observed37 and supported by our CCND1 knockdown study. The role of CCND1 in cell cycle control is well documented. CCND1 accumulates in cells at middle and late G1 phase and stimulate G1 progression to S phase. The proportion of parental cells in G1/0 correlated with the cisplatin sensitivity, with 833K cells having the highest G1/0 population cells and lowest EC50 value and GCT27 the lowest G1/0 population but highest EC50 score. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-302a | [3] | |||
Sensitive Disease | Testicular embryonal carcinoma [ICD-11: 2C80.1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | NCCIT cells | Embryo | Homo sapiens (Human) | CVCL_1451 |
NT2 cells | Prostate | Homo sapiens (Human) | CVCL_JA57 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Up-regulation of miR-302a significantly increased the sensitivity of NT2 cells to cisplatin by enhancing cisplatin-induced G2/M phase arrest and the subsequent progression to apoptosis. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.